局部胰腺导管腺癌新辅助治疗联合切除后的实际五年生存率
该多中心回顾性队列纳入2015年1月至2021年2月接受新辅助治疗联合根治性胰腺切除的660例局部胰腺导管腺癌患者,实际五年生存率为34.5%。复发以早期为主,术后1年、2年无复发者五年生存概率分别升至62.0%和81.9%。
要点
- 新辅助治疗后切除的局部PDAC实际五年生存率为34.5%,逾三分之一长期存活。
- 复发多发生于术后早期,近三分之二早期复发出现在术后1年内。
- 术后1年和2年无复发者五年生存概率分别为62.0%和81.9%。
核心结论
- 局部PDAC接受新辅助治疗联合切除后,超过三分之一患者五年时仍存活,且多数无病生存。
- 长期结局主要由早期全身性失败决定,延迟出现的寡转移复发提示存在生存期较长的亚组。
研究设计与样本
- 2家高容量中心2015年1月至2021年2月连续病例的回顾性队列研究。
- 仅纳入随访完整(死亡或≥5年)的患者,共660例接受新辅助治疗联合根治性胰腺切除的局部PDAC患者。
- 主要终点为自手术起算的实际五年生存率。
主要发现
- 660例患者实际五年生存率为34.5%。
- 复发率74.1%,复发以早期为主,未达五年生存者中近三分之二复发发生在术后1年内。
- 长期生存者复发率较低(92/228,40.4%),更多表现为延迟(>2年)、局部区域或肺部复发。
- 术后1年和2年仍无复发者达到五年生存的概率分别为62.0%(95% CI:56-67)和81.9%(95% CI:76-86)。
- 诊断时可切除、交界可切除、局部晚期患者的实际五年生存率分别为42.5%、29.0%、17.5%。
关键数值与推荐
- 长期生存的独立预测因素包括合并症负担低、基线CA19-9<200 U/mL、诊断时为可切除疾病、ypT0-1分期及R0切除。
- 术后1年无复发者五年生存概率62.0%(95% CI:56-67)。
- 术后2年无复发者五年生存概率81.9%(95% CI:76-86)。
临床怎么用
- 可依据诊断分期(可切除、交界可切除、局部晚期)向患者说明实际五年生存率的差异。
- 术后1年、2年无复发可作为评估长期生存可能性的重要时间节点。
- 关注合并症负担、基线CA19-9、ypT分期与R0切除等影响长期生存的因素。
局限性
- 为回顾性队列研究,仅纳入随访完整(死亡或≥5年)的患者。
- 研究仅来自2家高容量中心,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine actual 5-year survival after neoadjuvant therapy and resection for pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Long-term outcomes after neoadjuvant therapy and resection for PDAC remain poorly defined, as current knowledge largely relies on actuarial estimates. METHODS: Retrospective cohort study of consecutive patients who underwent neoadjuvant therapy followed by curative-intent pancreatectomy for localized PDAC at 2 high-volume centers between January 2015 and February 2021. Only patients with complete follow-up (death or ≥5 y) were included. The primary endpoint was actual 5-year survival from surgery. RESULTS: Among 660 patients, actual 5-year survival was 34.5%. Recurrence occurred in 74.1% and was predominantly early, with nearly two-thirds of recurrences among patients who did not achieve 5-year survival occurring within 1 year after surgery. Long-term survivors had lower recurrence rates (92/228, 40.4%) and more commonly developed delayed (>2 y), locoregional, or pulmonary recurrence. The probability of achieving 5-year survival increased to 62.0% (95% CI: 56-67) and 81.9% (95% CI: 76-86) among patients who remained recurrence-free at 1 and 2 years, respectively. Actual 5-year survival was 42.5%, 29.0%, and 17.5% in patients with resectable, borderline-resectable, and locally advanced disease at diagnosis, respectively. Independent predictors of long-term survival included low comorbidity burden, baseline CA19-9 <200 U/mL, resectable disease at diagnosis, ypT0-1 stage, and R0 resection. CONCLUSIONS: Over one-third of patients undergoing neoadjuvant therapy and resection for localized PDAC were alive at 5 years, and most remained disease-free. Long-term outcomes were primarily determined by early systemic failure, whereas delayed oligometastatic recurrence identified a subgroup with prolonged survival.
引用
- De Stefano F, Belfiori G, Wu NF, et al. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2026. PMID: 42717278. doi:10.1097/SLA.0000000000007214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。